Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05218811 · ClinicalTrials.gov registry record · NA

Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach

A NA study of Kidney Neoplasms, sponsored by Urological Research Network.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT05218811 is a NA study of Kidney Neoplasms that is actively recruiting participants, run by Urological Research Network. The registered enrollment target is 150 participants, below the 371-participant average among 9 other Kidney Neoplasms trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05218811, a NA study of Kidney Neoplasms, is actively recruiting participants, sponsored by Urological Research Network.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

Patients with renal masses eligible to partial nephrectomy often require arterial ischemia to control or prevent blood loss during this surgical procedure. This study aims to determine the safety and efficacy of renal cryoablation at the tumor bed, as a substitute measure or technique vs total or selective arterial renal ischemia.

Conditions Studied

Interventions

  • DEVICE Cryoablation Assisted Partial Nephrectomy

Study Locations (1)

Florida

  • Urological Research Network - Miami Lakes

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2020-05-15
Est. Completion 2041-05-15
Phase NA

Sponsor

Urological Research Network

4 total trials

What the Registry Record Tells You About NCT05218811

The ClinicalTrials.gov registry entry for NCT05218811 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 371-participant average among 9 other Kidney Neoplasms trials with a reported enrollment target (60% lower). The listed sponsor is Urological Research Network, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Kidney Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Cryoablation Assisted Partial Nephrectomy is the first listed.

NCT05218811 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05218811 about?

NCT05218811 is a clinical study titled "Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach". Patients with renal masses eligible to partial nephrectomy often require arterial ischemia to control or prevent blood loss during this surgical procedure. This study aims to determine the safety and efficacy of renal cryoablation at the tumor bed, as a substitute measure or technique vs total or se...

What is the current status of trial NCT05218811?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2020-05-15. Estimated completion is 2041-05-15.

What conditions does trial NCT05218811 study?

This clinical trial studies the following conditions: Kidney Neoplasms.

What interventions are being tested in trial NCT05218811?

The interventions under investigation include: Cryoablation Assisted Partial Nephrectomy (DEVICE).

Who is sponsoring clinical trial NCT05218811?

This trial is sponsored by Urological Research Network, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05218811 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Kidney Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.